文献速递类风湿关节炎其他结缔组织病

利妥昔单抗延缓类风湿关节炎相关间质性肺病进展的疗效:NEREA登记数据

Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

基于NEREA登记的多中心纵向研究纳入68例类风湿关节炎相关间质性肺病(RA-ILD)患者,评估利妥昔单抗(RTX)暴露与功能性呼吸损害(FVC预测值下降≥5%)的关系。结果显示RTX暴露者发生功能性呼吸损害的风险低于未暴露者(HR 0.51,95%CI 0.31–0.85),间质性肺炎、糖皮质激素、疾病活动度及病程亦影响该结局。

要点

  • RTX暴露与RA-ILD患者功能性呼吸损害风险降低相关(HR 0.51)。
  • RA-ILD患者中位无功能损害生存时间不足2年。
  • 间质性肺炎、糖皮质激素、疾病活动度及病程也影响功能损害。

核心结论

  • RA-ILD患者肺功能随时间恶化,中位无功能损害时间不足2年,RTX暴露者保持无功能损害的概率高于其他治疗。

研究设计与样本

  • 2007至2018年马德里多中心纵向研究,患者自ILD诊断起纳入NEREA登记,共纳入68例RA-ILD患者。
  • 主要终点为功能性呼吸损害,即预测用力肺活量较前次下降≥5%,基线及每6–12个月随访测定肺功能。

主要发现

  • 42例发生功能性呼吸损害,发生率23.5/100患者-学期(95%CI 19–29.1),其中50%在ILD诊断后1.75年内发生。
  • 多因素分析显示RTX暴露较未暴露的功能性呼吸损害风险更低(HR 0.51,95%CI 0.31–0.85)。
  • 间质性肺炎、糖皮质激素、疾病活动度及病程亦影响功能性呼吸损害。

临床怎么用

  • 对RA-ILD患者可考虑使用RTX以降低功能性呼吸损害风险,并关注间质性肺炎、激素使用、疾病活动度及病程等影响因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To asses the clinical course in RA-related interstitial lung disease (RA-ILD) patients with and without rituximab (RTX). The influence of other variables was also evaluated. METHODS: A longitudinal multicentre study was conducted in RA diagnosed with ILD from 2007 until 2018 in Madrid. Patients were included in a registry [pNEumology RhEumatology Autoinmune diseases (NEREA)] from the time of ILD diagnosis. The main endpoint was functional respiratory impairment (FI), when there was a decline ≥5% in the predicted forced vital capacity compared with the previous one. Pulmonary function was measured at baseline and in follow-up visits every 6-12 months. The independent variable was therapy with RTX. Covariables included sociodemographic, clinical, radiological and other therapies. Survival techniques were used to estimate the incidence rate (IR) and 95% CI of functional impairment, expressed per 100 patient-semesters. Cox multivariate regression models were run to examine the influence of RTX and other covariates on FI. Results were expressed as the hazard ratio (HR) and CI. RESULTS: A total of 68 patients were included. FI occurred in 42 patients [IR 23.5 (95% CI 19, 29.1)] and 50% of them had FI within 1.75 years of an ILD diagnosis. A multivariate analysis showed that RTX exposure resulted in a lower risk of FI compared with non-exposure [HR 0.51 (95% CI 0.31, 0.85)]. Interstitial pneumonia, glucocorticoids, disease activity and duration also influenced FI. CONCLUSION: RA-ILD patients deteriorate over time, with the median time free of impairment being <2 years. Patients exposed to RTX had a higher probability of remaining free of FI compared with other therapies. Other factors have also been identified.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Vadillo C, Nieto MA, Romero-Bueno F, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford). 2020. PMID: 31990338. doi:10.1093/rheumatology/kez673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。